Drug Enforcement Administration November 2, 2023 – Federal Register Recent Federal Regulation Documents

Isaac Sved, M.D.; Decision and Order
Document Number: 2023-24153
Type: Notice
Date: 2023-11-02
Agency: Drug Enforcement Administration, Department of Justice
Osmin A. Morales, M.D.; Decision and Order
Document Number: 2023-24151
Type: Notice
Date: 2023-11-02
Agency: Drug Enforcement Administration, Department of Justice
Blue Mint Pharmacy; Decision and Order
Document Number: 2023-24150
Type: Notice
Date: 2023-11-02
Agency: Drug Enforcement Administration, Department of Justice
Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2024
Document Number: 2023-24282
Type: Notice
Date: 2023-11-02
Agency: Drug Enforcement Administration, Department of Justice
The Drug Enforcement Administration (DEA) proposes to establish the 2024 aggregate production quotas (APQ) for controlled substances in schedules I and II of the Controlled Substances Act (CSA) and the assessment of annual needs (AAN) for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. For the 2024 quota year, DEA intends to allocate procurement quotas to DEA-registered manufacturers of schedule II controlled substances on a quarterly basis. In order to address domestic drug shortages of controlled substances, procurement quota allocations will be divided between quantities authorized for domestic sales and quantities authorized for export sales.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.